Effects of intensive control of blood glucose and blood pressure on microvascular complications in patients with type II diabetes mellitus

International Journal of Ophthalmology

Volumn 6, Issue 2, 2013, Pages 141-145

  Zhu, Cai Hong ^a   Zhang, Shi Sheng ^a   Kong, Yan ^a   Bi, Yu Fang ^a   Wang, Ling ^a   Zhang, Qiong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Diabetic retinopathy; Intensive therapy; Microvascular complications

Indexed keywords

EID: 84885661615     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2013.02.06     Document Type: Article

References (11)

1. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317(7160): 703-713.
2. Albers JW, Herman WH, Pop-Busui R, Feldman E.L., Martin CL, Cleary PA, Waberski BH, Lachin JM. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010; 33(5): 1090-1096.
3. The ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24): 2560-2572.
4. ADVANCE Collaborative Group. MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590): 829-840.
5. Lunetta M, Infantone L, Calogero A.E., Infantone E. Increased urinary albumin excretion is a marker of risk for retinopathy and coronary heart disease in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 1998; 40(1): 45-51.
6. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P., Heller S, MacMahon S, Marre M., Neal B, Patel A, Woodward M., Chalmers J, ADVANCE Collaborative Group. Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 2009; 32(11): 2068-2074.
7. Beulens JW, Patel A, Vingerling J.R., Cruickshank JK, Hughes AD, Stanton A, Lu J., McG Thom SA, Grobbee DE, Stolk RP, AdRem Project Team and ADVANCE Management Committee ADVANCE management committee. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia. 2009; 52(10): 2027-2036.
8. Brito JP, Montori VM. Intensive BP control and/or glucose control did not reduce microvascular events in hypertensive type 2 diabetes. Ann Intern Med. 2012; 157(8): JC4-7.
9. A CCORD Study Group; A CCORD Eye Study Group. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC, Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010; 363(3): 233-244.
10. Wilkinson CP, Ferris FL, 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, Global Diabetic Retinopathy Project Group Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003; 110(9): 1677-1682.
11. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000; 355(9200): 253-259.